Thyrocare Technologies Ltd
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
- Market Cap ₹ 3,492 Cr.
- Current Price ₹ 660
- High / Low ₹ 723 / 507
- Stock P/E 49.1
- Book Value ₹ 97.0
- Dividend Yield 2.71 %
- ROCE 18.6 %
- ROE 13.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 118%
- Debtor days have improved from 50.3 to 28.0 days.
Cons
- The company has delivered a poor sales growth of 7.19% over past five years.
- Promoters have pledged 100% of their holding.
- Working capital days have increased from 64.3 days to 106 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
134 | 150 | 180 | 235 | 298 | 332 | 370 | 401 | 474 | 562 | 486 | 524 | |
71 | 81 | 109 | 140 | 182 | 193 | 222 | 233 | 304 | 330 | 371 | 390 | |
Operating Profit | 64 | 69 | 71 | 95 | 115 | 139 | 148 | 168 | 171 | 232 | 115 | 134 |
OPM % | 47% | 46% | 40% | 40% | 39% | 42% | 40% | 42% | 36% | 41% | 24% | 26% |
18 | 7 | 13 | 6 | -16 | 21 | 14 | -35 | 12 | 7 | 5 | 7 | |
Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 4 |
Depreciation | 3 | 6 | 11 | 11 | 12 | 12 | 14 | 20 | 21 | 28 | 34 | 39 |
Profit before tax | 78 | 69 | 73 | 89 | 87 | 148 | 147 | 112 | 161 | 207 | 81 | 98 |
Tax % | 27% | 33% | 33% | 34% | 46% | 35% | 35% | 29% | 26% | 27% | 30% | 28% |
57 | 46 | 49 | 59 | 47 | 96 | 95 | 79 | 120 | 152 | 57 | 71 | |
EPS in Rs | 52.04 | 42.28 | 9.75 | 10.94 | 8.69 | 17.87 | 18.04 | 15.01 | 22.65 | 28.74 | 10.76 | 13.43 |
Dividend Payout % | 0% | 0% | 157% | 91% | 115% | 56% | 111% | 33% | 110% | 52% | 167% | 134% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 7% |
3 Years: | 3% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 4% |
5 Years: | -5% |
3 Years: | -15% |
TTM: | 29% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 7% |
3 Years: | -21% |
1 Year: | 24% |
Return on Equity | |
---|---|
10 Years: | 20% |
5 Years: | 21% |
3 Years: | 18% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11 | 11 | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 |
Reserves | 149 | 195 | 229 | 322 | 364 | 400 | 403 | 325 | 393 | 468 | 468 | 461 |
25 | 25 | 0 | 0 | 0 | 0 | 0 | 9 | 10 | 21 | 21 | 39 | |
11 | 14 | 14 | 39 | 26 | 31 | 32 | 55 | 73 | 55 | 70 | 68 | |
Total Liabilities | 197 | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 |
75 | 87 | 83 | 93 | 89 | 103 | 108 | 112 | 119 | 149 | 157 | 159 | |
CWIP | 10 | 6 | 6 | 1 | 2 | 0 | 1 | 4 | 8 | 2 | 1 | 1 |
Investments | 77 | 119 | 162 | 266 | 299 | 315 | 289 | 239 | 274 | 259 | 274 | 291 |
34 | 33 | 42 | 55 | 54 | 68 | 89 | 88 | 127 | 186 | 180 | 169 | |
Total Assets | 197 | 246 | 293 | 414 | 444 | 485 | 488 | 442 | 528 | 597 | 612 | 620 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
46 | 46 | 36 | 67 | 89 | 112 | 97 | 136 | 111 | 106 | 120 | 155 | |
-88 | -52 | -21 | -19 | -40 | -48 | -3 | 27 | -53 | -12 | -32 | -80 | |
1 | 0 | -23 | -45 | -48 | -65 | -96 | -163 | -58 | -87 | -88 | -84 | |
Net Cash Flow | -42 | -6 | -7 | 3 | 1 | -1 | -3 | 1 | 0 | 6 | 1 | -9 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 9 | 12 | 9 | 11 | 7 | 10 | 11 | 14 | 34 | 60 | 63 | 28 |
Inventory Days | 54 | 54 | 47 | 54 | 64 | 66 | 54 | 60 | 50 | 54 | 63 | 106 |
Days Payable | 2 | 13 | 5 | 8 | 4 | 23 | 19 | 62 | 48 | 30 | 52 | 83 |
Cash Conversion Cycle | 61 | 53 | 51 | 57 | 68 | 53 | 46 | 12 | 37 | 84 | 74 | 51 |
Working Capital Days | 19 | 22 | 52 | 15 | 28 | 11 | 4 | -9 | 9 | 49 | 38 | 106 |
ROCE % | 50% | 33% | 27% | 27% | 29% | 33% | 31% | 36% | 37% | 41% | 15% |
Documents
Announcements
- Execution Of Business Transfer Agreement With Polo Labs Private Limited 6h
- Closure of Trading Window 25 Jun
- Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011. 25 Jun
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 24 Jun
-
Updates
12 Jun - Clarification in reference to the filing of Disclosure under SEBI (Prohibition of Insider Trading) Regulations 2015.
Annual reports
Concalls
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Jul 2020TranscriptNotesPPT
-
May 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
Jun 2019TranscriptPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Dec 2017Transcript PPT
World’s leading Diagnostic center Incorporated in the year 1996, as a single economical thyroid testing center in Mumbai and now has become the world's leading Diagnostic chain which offers a wide range of medical diagnostic tests and management of diseases and disorders. [1]